...
首页> 外文期刊>Haematologica >Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment | Haematologica
【24h】

Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment | Haematologica

机译:慢性口服抗凝剂治疗患者血栓形成性基因突变与临床出血的相互作用血液学

获取原文
           

摘要

We studied the prevalence of genetic thrombophilic mutations in patients on chronic oral anticoagulant treatment (OAT) who had bleeding complications. In a case-control study we found ten (12.8%) carriers of factor V Leiden and two (2.5%) carriers of the PT20210A mutation among 78 patients with a history of moderate-severe bleeding while on OAT, and seven (4.4%) and four (2.5%), respectively, among 156 matched patients with no bleeding while on OAT (odds ratio 3.1+/-1.6, p=0.026). In patients on chronic OAT, FV Leiden is a risk factor for moderate-severe bleeding.
机译:我们研究了患有出血并发症的慢性口服抗凝治疗(OAT)患者的遗传性血栓形成突变的患病率。在一项病例对照研究中,我们在78名接受OAT时有中度重度出血病史的患者中发现了十个(12.8%)的V型莱顿因子携带者和两个(2.5%)的PT20210A突变携带者,还有七个(4.4%)分别在156例接受OAT时无出血的匹配患者中,有4例(2.5%)(赔率3.1 +/- 1.6,p = 0.026)。对于患有慢性OAT的患者,FV Leiden是中度重度出血的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号